AI Article Synopsis
- The study compares the effectiveness of two treatment regimens, FOLFIRINOX and GEM-NAB, for pancreatic ductal adenocarcinoma, aiming to identify which regimen is more effective in cytoreduction.
- A meta-analysis incorporated data from 40 studies involving 2883 patients, finding that while both regimens had similar overall response rates (ORR) of around 30%, FOLFIRINOX exhibited a higher disease control rate (DCR) of 85% compared to GEM-NAB's 80%.
- Although no significant superiority was found between the regimens in terms of RECIST-based cytoreduction, the study suggests further investigation into the better DCR
Article Abstract
Background: In pancreatic ductal adenocarcinoma cytoreduction can be curative, or palliative. FOLFIRINOX and GEM-NAB are the two FDA/EMA approved regimens for advanced disease. We aim to identified the most cytoreductive regimen on the basis of current literature.
Material And Methods: PUBMED was searched for studies published to April 2021. Abstracts of annual meetings ASCO 2009-2021, and ESMO 2015-2020, were searched as well. Phase II, phase III clinical trials, prospective, observational and retrospective studies, reporting overall response rate (complete + partial response) (ORR) in patients treated either with FOLFIRINOX or GEM-NAB were included. The meta-analysis was performed using a randomized-effects model. Main outcome was cytoreduction with each regimen reported as ORR according to RECIST.
Results: Among 2183 studies identified, 40 fulfilled the selection criteria (22 FOLFIRINOX, 18 GEM-NAB), totaling 2883 patients. Pooling of data found similar ORR between regimens: FOLFIRINOX [30% (95 CI 26-34%)] and GEM-NAB [30% (95 CI 26-35%),] P = 0.928. Disease control rate (DCR) was significantly higher with FOLFIRINOX [85% (95CI 82-88%)] compared to GEM-NAB [80% (95CI 77-84%)], P = 0.012. A significantly higher ORR irrespective of the regimen was observed in stage IV [36% (95CI 32-40%)] versus stage II-III [25% (95CI 20-31%)], P = 0.002.
Conclusions And Relevance: Our meta-analysis did not find significant superiority of one regimen over the other in terms of RECIST-based cytoreduction both in palliative and curative setting of patients with pancreatic adenocarcinoma. The significantly better DCR with FOLFIRINOX compared with GEM-NAB deserves further investigation including waterfall plot and correlations with potential predictive factors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctrv.2022.102338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which is Best?
Ann Surg
December 2024
Department of Surgery, Stanford University, Stanford, CA.
Objective: To examine the optimal method of assessing response to neoadjuvant therapy (NAT) in operable pancreatic ductal adenocarcinoma (PDAC) patients.
Summary Of Background Data: PDAC response to NAT is measured with biochemical, radiographic and pathologic parameters, which can often be discordant with each other.
Methods: PDAC patients undergoing resection after NAT at a single institution were retrospectively analyzed.
Metastatic pancreatic ductal carcinoma (mPDAC) is one of the most lethal malignancies. The European Society for Medical Oncology (ESMO) guidelines recommend a gemcitabine doublet + nab-paclitaxel (Gem/Nab-P) or a modified FOLFIRINOX regimen (mFOLFIRINOX) as options for systemic chemotherapy. Gemcitabine monotherapy is an option for patients in a worse performance status (PS).
View Article and Find Full Text PDFBackground: Advanced pancreatic ductal adenocarcinoma (PDAC) remains a disease with a dismal prognosis, significantly limited therapeutic options, and few innovative drugs. Inflammation plays a significant role in the development and progression of PDAC. Systemic inflammatory indexes reflect the anti-tumor inflammatory capacity of and are of prognostic and predictive value in the treatment of patients with PDAC.
View Article and Find Full Text PDFEvaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Study.
Pancreas
July 2024
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Objectives: To clarify the treatment reality of pancreatic cancer in Japan, focusing on treatment duration and time to death.
Materials And Methods: We retrospectively analyzed Japanese hospital claims data for patients diagnosed with pancreatic cancer between April 2009 and October 2018 to investigate treatment patterns, duration of first-line chemotherapy, and time to death.
Results: Of 81,185 eligible patients, 54.
Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy.
JCO Precis Oncol
September 2023
Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA.
Purpose: Pancreatic adenocarcinoma is an aggressive disease with poor clinical outcomes. Primary pancreatic tumors originating from the head of the pancreas (H) have different prognostic implications than tumors arising from the body and tail (BT). This is thought to be largely due to anatomic differences, as molecular underpinnings of survival have not been fully explored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!